Xanthone-1,2,4-triazine and Acridone-1,2,4-triazine Conjugates: Synthesis and Anticancer Activity

• Main Authors: Sougata Santra (Author), Ainur D. Sharapov (Author), Ramil F. Fatykhov (Author), Anastasya P. Potapova (Author), Igor A. Khalymbadzha (Author), Maria I. Valieva (Author), Dmitry S. Kopchuk (Author), Grigory V. Zyryanov (Author), Alexander S. Bunev (Author), Vsevolod V. Melekhin (Author), Vasiliy S. Gaviko (Author), Andrey A. Zonov (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

A total of 21 novel xanthone and acridone derivatives were synthesized using the reactions of 1,2,4-triazine derivatives with 1-hydroxy-3-methoxy-10-methylacridone, 1,3-dimethoxy-, and 1,3-dihydroxanthone, followed by optional dihydrotiazine ring aromatization. The synthesized compounds were evaluated for their anticancer activity against colorectal cancer HCT116, glioblastoma A-172, breast cancer Hs578T, and human embryonic kidney HEK-293 tumor cell lines. Five compounds (<b>7a</b>, <b>7e</b>, <b>9e</b>, <b>14a</b>, and <b>14b</b>) displayed good in vitro antiproliferative activities against these cancer cell lines. Compounds <b>7a</b> and <b>7e</b> demonstrated low toxicity for normal human embryonic kidney (HEK-293) cells, which determines the possibility of further development of these compounds as anticancer agents. Annexin V assay demonstrated that compound <b>7e</b> activates apoptotic mechanisms and inhibits proliferation in glioblastoma cells.

Item Description

10.3390/ph16030403
1424-8247